TABLE 13Non-haematological AEs (grades 3 and 4) with dasatinib (%)

Adverse eventKantarjian et al. (2007),6 70 mg b.i.d. (n = 101)Kantarjian et al. (2009),7 70 mg b.i.d. (n = 101)
Abdominal pain0
Anorexia0.00
Asthenia0.00
Bleeding1
Diarrhoea2.03
Dyspnoea4.05
Face oedema0.0
Fatigue2.03
Fluid retention7
Headache2.02
Infection4
Muscle spasms0.0
Musculoskeletal pain1
Nausea0.00
Pain in extremity0.0
Peripheral oedema0.0
Pleural effusion4.05
Pyrexia0.00
Rash0.00
Superficial oedema0.01
Vomiting0.00
Weight increase0.0

Data are as presented by the publications, i.e. rounded or to one decimal place.

From: 3, Clinical effectiveness

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.